Twenty One Capital Inc (CEP) Stock News

A securities fraud class action lawsuit has been filed against PROCEPT BioRobotics Corporation for allegedly making materially false statements about product demand. The company allegedly used undisclosed discount programs to inflate handpiece unit sales, resulting in overstocking. PROCEPT's stock fell over 18% on February 25, 2026, when the company revealed that handpiece sales had consistently exceeded procedures. Investors have until September 22, 2026, to seek lead plaintiff status.

Rosen Law Firm is seeking lead plaintiffs for a securities class action lawsuit against PROCEPT BioRobotics Corporation. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales figures. The company allegedly accumulated over 10,000 excess units in field inventory and was unable to achieve its 2025 guidance. The lead plaintiff deadline is September 22, 2026.

PROCEPT BioRobotics faces a securities class action lawsuit for allegedly failing to disclose material information about excess handpiece inventory and inflated sales figures during the Class Period (February 28, 2024 - February 25, 2026). The company is accused of misleading investors about U.S. handpiece sales that exceeded procedures, resulting in over 10,000 units of excess inventory that would cause significant revenue declines. Investors with losses exceeding $100,000 have until September 22, 2026 to file lead plaintiff applications.

Kaplan Fox & Kilsheimer LLP has filed class action lawsuits against PROCEPT BioRobotics Corporation for allegedly using undisclosed discount programs that artificially inflated handpiece unit sales and revenues during the Class Period (February 28, 2024 - February 25, 2026). The firm is also pursuing cases against Hub Group, Inc. and investigating potential securities violations at Alignment Healthcare, Inc. Investors with losses are encouraged to contact the firm before respective deadlines.

Grabar Law Office has filed federal securities fraud class action investigations against four companies: Erasca for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet for defective manufacturing controls leading to voluntary product corrections; Power Solutions for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics for using undisclosed discount programs that artificially inflated sales and created excess inventory. Shareholders who purchased shares during specified periods are eligible to seek damages and corporate reforms.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation alleging securities fraud. The company allegedly failed to disclose an extensive discount program that artificially inflated handpiece sales and revenues between February 2024 and February 2026. The undisclosed practices led to excess field inventory exceeding 10,000 units and significant stock price declines following quarterly earnings announcements. Shareholders who purchased PROCEPT securities during the class period have until September 22, 2026 to file a lead plaintiff motion.

Grabar Law Office has launched investigations into potential securities fraud and fiduciary duty breaches at four major companies: Erasca (ERAS) for misleading statements about its ERAS-0015 drug candidate and undisclosed patent risks; Insulet (PODD) for defective manufacturing controls leading to voluntary product corrections; Power Solutions International (PSIX) for overstating sales demand and understating manufacturing costs; and PROCEPT BioRobotics (PRCT) for using undisclosed discount programs that artificially inflated sales figures and created excess inventory.

Rosen Law Firm has filed class action lawsuits against PROCEPT BioRobotics Corporation for allegedly making materially false statements regarding sales practices. The lawsuit claims PROCEPT used undisclosed discount programs to artificially inflate handpiece unit sales and revenues, created excess inventory of over 10,000 units, and provided unrealistic 2025 guidance. Investors who purchased stock between February 28, 2024 and February 25, 2026 may be eligible for compensation. The deadline to serve as lead plaintiff is September 22, 2026.

Robbins Geller has filed a class action lawsuit against PROCEPT BioRobotics Corporation, alleging that the company and its executives made materially false and misleading statements regarding undisclosed discount programs that artificially inflated sales figures and created excess field inventory. The lawsuit covers investors who purchased PRCT stock between February 28, 2024 and February 25, 2026. Multiple stock price declines followed earnings announcements revealing lower-than-expected handpiece sales and inventory management issues.

Rosen Law Firm has filed a securities class action lawsuit against PROCEPT BioRobotics Corporation on behalf of investors who purchased common stock between February 28, 2024 and February 25, 2026. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales figures and created excess inventory of over 10,000 units. The firm claims the company's 2025 guidance lacked a reasonable factual basis. Investors must move the court by September 22, 2026 to serve as lead plaintiff.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation alleging the company issued materially false statements regarding its handpiece unit sales and revenues. The complaint claims PROCEPT used an undisclosed discount program to artificially inflate sales figures, created excess field inventory of over 10,000 units, and failed to disclose material risks. The lead plaintiff deadline is September 22, 2026.

PROCEPT BioRobotics faces a securities class action lawsuit for allegedly failing to disclose material information about excess handpiece inventory and inflated sales figures during the Class Period (February 28, 2024 - February 25, 2026). Investors with losses exceeding $100,000 have until September 22, 2026 to file lead plaintiff applications.

PROCEPT BioRobotics faces a securities class action lawsuit for failing to disclose material inventory issues. The company revealed on February 25, 2026 that handpiece sales had materially exceeded procedures since Q1 2023, resulting in over 10,000 units of excess field inventory. This disclosure caused the stock to decline approximately 18% in two days, from $27.84 to $22.69 per share. Investors who purchased shares between February 28, 2024 and February 25, 2026 can file lead plaintiff applications by September 22, 2026.

Rosen Law Firm has filed a class action lawsuit against PROCEPT BioRobotics Corporation on behalf of investors who purchased common stock between February 28, 2024 and February 25, 2026. The lawsuit alleges that PROCEPT made materially false statements regarding its handpiece unit sales and revenues by utilizing an undisclosed discount program that artificially inflated sales figures and created excess inventory of over 10,000 units. The company allegedly failed to disclose these risks and was unable to achieve its 2025 guidance. Investors must move the court by September 22, 2026 to serve as lead plaintiff.

Grabar Law Office has initiated investigations on behalf of shareholders of four NASDAQ-listed companies: Cogent Communications (CCOI), EquipmentShare (EQPT), Photronics (PLAB), and PROCEPT BioRobotics (PRCT). The investigations allege breaches of fiduciary duties, including misrepresentation of business fundamentals, undisclosed related-party transactions, false demand statements, and artificially inflated sales figures. Shareholders who purchased shares before specified dates and still hold them may seek corporate reforms and damages at no cost.

A securities class action lawsuit has been filed against PROCEPT BioRobotics Corporation on behalf of investors who purchased stock between February 28, 2024 and February 25, 2026. The lawsuit alleges the company made materially false and misleading statements regarding business operations, growth prospects, and financial stability, causing stock prices to trade at artificially inflated levels. Investors suffered significant losses when the truth was disclosed.

A class action lawsuit has been filed against PROCEPT BioRobotics Corporation, alleging that the company and its executives made materially false and misleading statements regarding sales practices. The lawsuit claims PROCEPT used undisclosed discount programs that artificially inflated handpiece unit sales and revenues, created excess field inventory of over 10,000 units, and issued unrealistic guidance. Stock price declined significantly following earnings announcements in August 2025, November 2025, and February 2026.

Olson Wealth Group, founded by Sharon Olson (CFP®, CEPA), has expanded its integrated exit and liquidity planning services for business owners and entrepreneurial families. The firm now coordinates business strategy, tax planning, estate planning, and family office services years before a transaction occurs, aiming to maximize enterprise value and prevent value erosion that often occurs when planning begins too late in the process.

Moderna announced positive five-year follow-up results from its Phase 2b trial showing its melanoma vaccine candidate (intismeran autogene plus KEYTRUDA) reduced recurrence or death risk by 49% compared to KEYTRUDA alone. The company also expanded its partnership with CEPI to develop a Bundibugyo ebolavirus vaccine, with CEPI committing up to $50 million. Despite the positive news, Moderna's stock fell 2.78% to $45.88.

Moderna, Inc. (NASDAQ: MRNA ) stock is trading lower on Monday. The COVID-19 vaccine maker and Merck & Co Inc . (NYSE: MRK ) reported five-year follow-up results from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of individualized neoantigen therapy intismeran autogene (mRNA-4157/V940) plus KEYTRUDA for high-risk stage III/IV melanoma after complete surgical resection. • Moderna stock is under selling pressure. What’s driving MRNA stock lower? Combination Continues To Show Durable Melanoma Benefits After a median follow-up of 60.3 months, the combination continued to show durable benefits, reducing the risk of recurrence or death by 49% compared with KEYTRUDA alone, meeting the study’s primary endpoint of recurrence-free survival (RFS) . The combination also improved the key secondary endpoint of distant metastasis-free survival (DMFS), lowering the risk of distant metastasis or death by 59% versus KEYTRUDA alone. data-variant="card" data-news-mode="manual" > Read ... Full story available on Benzinga.com

Austin, Texas , May 26, 2026 (GLOBE NEWSWIRE) -- FOR IMMEDIATE RELEASE MEDX HOLDINGS (MEDH) REPORTS EXCEPTIONAL Q1 2026 FINANCIALS: REVENUE SURGES, EXPANSION ON TRACK, AND CEO TO SPEAK AT HEMP BEVERAGE EXPO AUSTIN, Texas — May 26, 2026 — MedX Holdings, Inc. (OTC: MEDH ) (soon to be Dazed Inc., pending ticker symbol DAZE), a dynamic brands and acquisition company focused on the emerging hemp, cannabis, and hospitality industries, today announced its financial results for the first quarter ended March 31, 2026. The company is thrilled to report significant year-over-year revenue and gross profit growth, continued profitability, and major traction in its nationwide franchise expansion. Q1 2026 Financial Highlights: Accelerated Growth and Profitability The first quarter of 2026 reflects the power of MedX's strategic focus on high-margin branding, efficient operations, and calculated expansion. Key financial milestones from the Q1 2026 consolidated financial statements include: Solid Revenue Growth: Q1 2026 revenues reached $521,874, representing an impressive 52.7% increase compared to revenues of $341,711 in Q1 2025. Surging Gross Profit: Gross profit for the quarter climbed to $398,990, a 70.6% jump from the $233,793 reported in the same period last year. Sustained Profitability: The company maintained a positive bottom line, reporting a net income of $22,203 for the three months ended March 31, 2026. Expansion on Track: Bringing the "Third Place" to New Cities Following the momentum built in late 2025, ... Full story available on Benzinga.com

Potomac Bancshares, Inc. held its annual shareholder meeting on May 19, 2026, in Shepherdstown, West Virginia. The company reported successful growth and progress on strategic initiatives in 2025, highlighted the positive transition from Bank of Charles Town to Potomac Bank, and elected new board members. The bank reported total assets of $976 million as of March 31, 2026, and operates through nine branches across West Virginia, Maryland, and Northern Virginia.